# Phototherapy Market

> 光疗市场研究报告信息按产品（传统光疗设备、LED光疗设备、光纤光疗设备、杀菌灯及配件）、辐射（UVA、UVB和UVC）、应用（皮肤病治疗、新生儿黄疸管理和消毒）、最终用户（医院和诊所、皮肤科中心和家庭护理）及地区（美洲、欧洲、亚太地区和中东及非洲） - 增长和行业预测2025至2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.12%
- **2024:** $ 0.62 Billion
- **2025:** $ 0.65 Billion
- **2035:** $ 1.07 Billion
- **Key Players:** Philips (NL), GE Healthcare (US), Natus Medical Incorporated (US), Daavlin (US), Hill-Rom Holdings, Inc. (US), Bio-Therapeutics, Inc. (US), Sunlight Medical (US), Waldmann (DE), Lumenis (IL)

**Report ID:** MRFR/MED/1312-CR · **Pages:** 168 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 11, 2026

**URL:** https://www.marketresearchfuture.com/reports/phototherapy-market-1844

---

## Market Summary

As per Market Research Future analysis, The Global Phototherapy Market Size was estimated at 0.62 USD Billion in 2024. The phototherapy industry is projected to grow from USD 0.6517 Billion in 2025 to USD 1.074 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.12% during the forecast period 2025 - 2035

## Market Drivers

### Supportive Regulatory Framework

一个支持性的监管框架正在促进全球光疗行业的增长。监管机构越来越认识到光疗的有效性，从而简化了新设备和治疗的审批流程。这种监管支持不仅鼓励创新，还增强了制造商和医疗服务提供者的信心。截至2025年10月，几种新的光疗设备已获得加速批准，促进了它们进入市场。这一趋势预计将持续，监管机构可能会优先审查光疗技术，从而增强市场动态并鼓励进一步的研发投资。

### Increasing Incidence of Skin Disorders

皮肤疾病（如银屑病、湿疹和痤疮）的日益普遍是全球光疗行业的主要驱动力。根据最近的估计，皮肤疾病影响着全球数百万人的生活，导致对有效治疗方案的需求不断增长。光疗市场因其非侵入性和经过验证的有效性而成为首选。预计市场将在未来几年内实现显著增长，年均复合增长率（CAGR）约为7%。这一趋势表明市场潜力强劲，医疗服务提供者越来越推荐光疗作为多种皮肤病的可行治疗方案。

### Growing Awareness of Phototherapy Benefits

对光疗益处的认识不断提高是全球光疗行业的重要驱动力。关于光疗在治疗各种皮肤病方面有效性的教育活动和信息传播的增加，导致医疗专业人员和患者的接受度提高。截至2025年，调查显示约60%的皮肤科医生推荐光疗作为某些皮肤疾病的一线治疗。这种日益增长的支持可能会增强患者对光疗的信心，从而推动市场增长。此外，媒体和患者见证中成功治疗结果的日益可见性也促进了这种认识的提高。

### Rising Demand for Home-Based Treatment Options

对家庭治疗选择的日益偏好正在重塑全球光疗行业。患者越来越寻求可以在家中舒适环境中进行的方便有效的解决方案。这一趋势源于对隐私、成本效益和易用性的渴望。因此，制造商正在开发适合家庭使用的用户友好型光疗设备。预计家庭光疗设备市场在未来几年将以约8%的年均复合增长率增长，表明治疗方式向更易获取的方向转变。这一演变反映了医疗保健中的更广泛趋势，即患者被赋予控制自己治疗的权力。

### Technological Innovations in Phototherapy Devices

光疗设备的技术进步正在显著影响全球光疗行业。基于LED的系统和便携设备等创新提高了治疗效果和患者便利性。智能光疗设备的推出，允许远程监控和个性化治疗计划，预计将进一步推动市场增长。截至2025年，先进光疗设备的市场预计将达到超过10亿美元的估值，反映出对皮肤病治疗中尖端技术的日益偏好。这些创新不仅改善了患者的治疗效果，还扩大了光疗治疗的可及性。

## Future Outlook

预计全球光疗市场将在2025年至2035年间以5.12%的年均增长率增长，推动因素包括技术进步、皮肤疾病增加和对光疗益处的认识提高。

到2035年，市场预计将实现显著增长，巩固其作为关键治疗选择的地位。

## Segment Insights

### 按产品：LED光疗设备（最大）与光纤光疗设备（增长最快）

在全球光疗市场中，各种产品细分的分布显示LED光疗设备是最重要的参与者，由于其效率和有效性，在不同地区占据市场份额。传统光疗设备紧随其后，受益于长期的临床使用，而杀菌灯和配件在销售中占据重要部分，特别是在医疗保健环境中。光纤光疗设备虽然相对较小，但因其创新设计和在新生儿护理中的特定应用而备受关注。近年来，光疗细分市场经历了显著增长，主要受到皮肤疾病发生率上升和对光疗益处认识提高的推动。技术进步增强了LED和光纤光疗的吸引力，导致它们在医院和诊所的快速采用。此外，医疗保健专业人员越来越认识到杀菌灯的治疗潜力，推动其在医疗设施中的感染控制管理中的使用。

技术：LED光疗设备（主导）与光纤光疗设备（新兴）

LED光疗设备在市场中占据主导地位，为各种皮肤病提供节能和多功能的治疗选择，包括银屑病和湿疹。其能够产生特定波长的光，使其成为皮肤科医生和消费者的首选。同时，光纤光疗设备作为一种创新解决方案，特别适合治疗新生儿高胆红素血症，确保有效治疗且不适感最小。虽然LED细分市场需求强劲，但光纤技术因对儿科护理中先进疗法的日益关注而扩大市场份额。这种对比体现了光疗领域内更广泛的动态，其中成熟技术与新颖创新共存并竞争，以满足不断变化的医疗需求。

### 按辐射：紫外线B（UVB）（最大）与补骨脂紫外线A（PUVA）（增长最快）

在全球光疗市场中，紫外线B（UVB）细分已确立为最大的贡献者，由于其在治疗各种皮肤病（特别是银屑病和湿疹）方面的有效性，主导市场份额。这种方法涉及使用特定波长，已被皮肤科医生广泛接受。相比之下，补骨脂紫外线A（PUVA）细分虽然市场份额较小，但由于其独特的能力治疗更严重的皮肤病，正在迅速追赶，成为光疗提供商增长战略中的关键参与者。

紫外线B（主导）与补骨脂紫外线A（新兴）

紫外线B（UVB）细分以其成熟的技术和在临床环境中的广泛接受度为特征，主要集中于皮肤病。其主导地位源于良好的疗效和良好的安全性。相反，补骨脂紫外线A（PUVA）细分正在迅速崛起，以其对更具挑战性的皮肤病（包括皮肤淋巴瘤）的有效性而闻名。对PUVA治疗的认识和接受度不断提高，加上技术进步提高了安全性和便利性，推动了该细分市场的扩展。随着患者寻求更多样化的疗法，这两个细分市场在光疗领域中提供了重要的选择。

### 按应用：皮肤病治疗（最大）与新生儿黄疸管理（增长最快）

全球光疗市场的应用领域多样，皮肤病治疗占据最大的市场份额。该细分市场至关重要，受到银屑病和湿疹等皮肤病发病率上升的推动，这些病症严重依赖有效的光疗解决方案。同时，新生儿黄疸管理已成为增长最快的细分市场，得益于对新生儿健康的认识提高和光疗技术的进步，提高了治疗效果。总体而言，随着医疗保健专业人员越来越多地采用光疗用于各种病症，这些应用领域仍有显著的持续增长机会。

皮肤病治疗（主导）与新生儿黄疸管理（新兴）

在全球光疗市场中，皮肤病治疗仍然是主导应用，主要用于缓解与慢性病相关的症状。该细分市场专注于基于光的疗法，这些疗法因其在治疗银屑病、痤疮和其他皮肤病方面的有效性而被广泛接受。相比之下，新生儿黄疸管理是一个新兴细分市场，利用对新生儿医疗保健日益重视的趋势。使用光疗治疗新生儿黄疸涉及明亮的光照射以降低胆红素水平，技术创新提高了此类治疗的安全性和有效性。这两个细分市场突显了基于光的疗法在改善患者结果中的关键作用。

### 按最终用户：诊所（最大）与家庭护理（增长最快）

在全球光疗市场中，诊所占据最大的份额，因为它们是光疗治疗的主要场所。它们提供专业服务和个性化护理，使其成为寻求治疗光疗的患者的首选。紧随其后的是医院和[皮肤科](../../../reports/dermatology-diagnostic-device-market-2154)中心，在先进治疗和研究中也发挥着重要作用，但家庭医疗保健领域的增长正在迅速改变这一格局。

家庭护理：新兴与诊所：主导

诊所仍然是光疗市场的主导参与者，因其成熟的基础设施、经验丰富的专业人员和广泛的治疗选择。然而，家庭护理的兴起是一个显著趋势，受到患者对便利性偏好的增加和在自己环境中管理治疗能力的驱动。患者从成本效益和灵活性中受益，技术正在发展以促进有效的家庭治疗解决方案。这一转变反映了医疗服务交付的更广泛转型，将传统临床服务与创新的家庭护理方法相结合。

## Regional Market Share Analysis

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Phototherapy Market accounted for USD 0.2 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The United States has been dominating the market landscape and has played an important role in influencing the overall market. The major reason for the outstanding performance of this Region is the high demand for phototherapy solutions for skin treatments.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Europe's market of phototherapy accounts for the second-largest share owing to technological advancements and various financial aids, encouraging opting for this treatment. In 2020, the market was valued at approximately USD 56 Billion, while the French were valued at USD 34 Billion. One of the big opportunities for medical device manufacturers is the creation and expansion of 40 major hospitals across England by 2030, according to HospeTrack UK hospital intelligence. 

At this point, another eight items may be added to the pipeline. The government's strong interest in improving its healthcare system is expected to boost the development of phototherapy treatments. Further, the Germany market of phototherapy held the largest market share, and the UK market of phototherapy was the fastest-growing market in the region.

The Asia Pacific Phototherapy Market is expected to grow at the fastest CAGR from 2022 to 2030. An increasing number of premature births and an increasing number of people suffering from skin diseases can be attributed to the high growth rate. For example, according to The Lancet, approximately 85% of preterm births occur late preterm, and 80% of these occur in Asia and South Asia. 

Moreover, according to the Narayan Health Organization, India alone accounts for one-fifth of the 15 billion preterm births worldwide. Moreover, people in the Asia Pacific are prone to acne, which is expected to drive phototherapy use further. Further, the India market of phototherapy held the largest market share, and the China market of phototherapy was the fastest-growing in the region.

## Competitive Benchmarking

Major market players are investing heavily in research and development to increase their product lines, which will help the market for Phototherapy Market to grow further. The market players have also undertaken several strategic initiatives to expand their footprints, including key market developments such as new product launches, contractual agreements, mergers and acquisitions, increasing investments, and collaborations with other organizations. Competitors in the Phototherapy industry must offer cost-effective products to expand and survive in the increasingly competitive and rising market environment. One of the key business strategies adopted by the manufacturers in the Phototherapy industry to benefit their customers and expand their market segment is to manufacture locally to reduce operating costs. In recent years, the Phototherapy industry has provided some of the most significant medical benefits. Major players in the Phototherapy Market, such as Signify Holding (Netherlands), G.E. Healthcare (U.S.), Natus Medical Incorporated (U.S.), Herbert Waldmann GmbH & Co. K.G. (Germany), Phoenix Medical Systems (P) Ltd (India), Atom Medical Corporation (Japan), National Biological Corporation (U.S.) are focusing on expanding the market demand by investing in research and development activities. Sewon Cellontech Co., Ltd. is engaged in the provision of mechatronics and regenerative medical system equipment. The company provides products such as petrochemical, refining, natural gas and power plant equipment, and exports plant equipment to countries such as the Middle East. On August 22, 2022, South Korea-based Sewon NC announced that it will commercialize organic light-emitting diode (OLED)-based phototherapy solutions for the treatment of pain and various skin conditions. The OLED optical patch developed by KAIST is a flexible platform that can be fixed on the body.  It's less than 1mm thick and relies on a flexible OLED screen. Preclinical trials using the patch will take place in the first half of 2022 with promising results. Sewon intends to expand the use of the patch in more areas, including the treatment of skin conditions, including wrinkles, skin cancer, dementia and other skin conditions. Also, GE HealthCare Technologies Inc., trading as GE Healthcare, is a medical technology company headquartered in Chicago, Illinois. It is a manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures. It manufactures medical diagnostic equipment, including CT imaging machines; MRI, X-rays; ultrasound; [cath lab](https://www.marketresearchfuture.com/reports/cath-lab-market-30430); mammography; nuclear medicine cameras; and develops applications in medical imaging and information technology, medical diagnostics, patient monitoring systems, disease research, drug discovery, and health technologies for biopharmaceutical manufacturing.  In November 2022, GE Healthcare and MediView XR Inc, announced their collaboration to integrate medical imaging into mixed reality solutions through the development of the OmnifyXRTM Interventional Suits System.

## Recent News & Developments

- **Q2 2024: Philips launches next-generation BlueControl wearable phototherapy device for psoriasis** Philips announced the launch of its new BlueControl wearable phototherapy device, designed to provide targeted blue LED light therapy for patients with mild to moderate plaque psoriasis. The device is CE-marked and aims to improve patient convenience and adherence to treatment.
- **Q1 2024: Biofrontera Inc. Announces FDA Approval of Ameluz® PDT Lamp for Expanded Indication** Biofrontera Inc. received FDA approval for its Ameluz® photodynamic therapy lamp to treat actinic keratosis on the extremities and trunk, expanding its previous indication limited to the face and scalp.
- **Q2 2024: Soligenix Announces Positive Results from Phase 3 FLASH Study of HyBryte™ in Cutaneous T-Cell Lymphoma** Soligenix reported positive topline results from its Phase 3 FLASH study evaluating HyBryte™, a synthetic hypericin photodynamic therapy, for the treatment of cutaneous T-cell lymphoma, supporting a future regulatory submission.
- **Q3 2024: Ra Medical Systems Completes Merger with Catheter Precision, Inc.** Ra Medical Systems completed its merger with Catheter Precision, Inc., combining their expertise in medical device development, including phototherapy and ablation technologies, to expand their therapeutic offerings.
- **Q2 2024: Dermal Photonics Corporation Raises $15 Million Series B to Advance At-Home Phototherapy Market Platform** Dermal Photonics Corporation closed a $15 million Series B funding round to accelerate the development and commercialization of its at-home phototherapy platform for dermatological conditions.
- **Q1 2025: Lumenis Announces Strategic Partnership with MedSkin Solutions for Advanced Phototherapy Market Applications** Lumenis entered into a strategic partnership with MedSkin Solutions to co-develop advanced phototherapy solutions targeting chronic wound care and skin regeneration.
- **Q2 2025: TheraLight Opens New Manufacturing Facility in Texas to Meet Growing Demand for Light Therapy Devices** TheraLight inaugurated a new manufacturing facility in Texas to increase production capacity for its full-body phototherapy devices, addressing rising demand in clinical and wellness markets.
- **Q1 2024: Vielight Receives Health Canada Approval for Neuro Alpha Photobiomodulation Device** Vielight received regulatory approval from Health Canada for its Neuro Alpha photobiomodulation device, enabling commercial distribution for cognitive health applications.
- **Q3 2024: PhotoMedex Appoints Dr. Lisa Grant as Chief Medical Officer** PhotoMedex announced the appointment of Dr. Lisa Grant as Chief Medical Officer to lead clinical strategy and oversee regulatory initiatives for its phototherapy product portfolio.
- **Q2 2025: BioLitec AG Receives CE Mark for New LEONARDO® Mini Dual Phototherapy Market Laser System** BioLitec AG obtained CE Mark approval for its LEONARDO® Mini Dual, a compact phototherapy laser system designed for minimally invasive dermatological and vascular treatments.
- **Q1 2025: Strata Skin Sciences Announces Distribution Agreement with Medline Industries for XTRAC® Laser System** Strata Skin Sciences entered into a distribution agreement with Medline Industries to expand the reach of its XTRAC® excimer laser phototherapy system for psoriasis and vitiligo treatment in the U.S.
- **Q2 2024: Theralase Technologies Receives FDA Breakthrough Device Designation for Anti-Cancer Photodynamic Therapy** Theralase Technologies was granted FDA Breakthrough Device Designation for its photodynamic therapy platform targeting non-muscle invasive bladder cancer, expediting regulatory review and development.

## Report Scope

| MARKET SIZE 2024 | 0.62(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.6517(USD Billion) |
| MARKET SIZE 2035 | 1.074(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.12% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Philips (NL), GE Healthcare (US), Natus Medical Incorporated (US), Daavlin (US), Hill-Rom Holdings, Inc. (US), Bio-Therapeutics, Inc. (US), Sunlight Medical (US), Waldmann (DE), Lumenis (IL) |
| Segments Covered | Product |
| Key Market Opportunities | Advancements in light-emitting diode technology enhance treatment efficacy in The Global Phototherapy. |
| Key Market Dynamics | Rising demand for non-invasive treatments drives innovation and competition in the phototherapy market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of The Global Phototherapy by 2035?**
A: The projected market valuation of The Global Phototherapy is expected to reach 1.074 USD Billion by 2035.

**Q: What was the market valuation of The Global Phototherapy in 2024?**
A: The overall market valuation of The Global Phototherapy was 0.62 USD Billion in 2024.

**Q: What is the expected CAGR for The Global Phototherapy during the forecast period 2025 - 2035?**
A: The expected CAGR for The Global Phototherapy during the forecast period 2025 - 2035 is 5.12%.

**Q: Which companies are considered key players in The Global Phototherapy?**
A: Key players in The Global Phototherapy include Philips, GE Healthcare, Natus Medical Incorporated, and Daavlin.

**Q: What are the main product segments in The Global Phototherapy?**
A: The main product segments in The Global Phototherapy include Conventional Phototherapy Equipment, LED Phototherapy Equipment, and Fiberoptic Phototherapy Equipment.

**Q: How much was the valuation for Ultraviolet B (UVB) radiation segment in 2024?**
A: The valuation for the Ultraviolet B (UVB) radiation segment was 0.25 USD Billion in 2024.

**Q: What applications are driving growth in The Global Phototherapy?**
A: Applications driving growth in The Global Phototherapy include Skin Disease Treatment, Neonatal Jaundice Management, and Sterilization.

**Q: What is the projected valuation for the LED Phototherapy Equipment segment by 2035?**
A: The projected valuation for the LED Phototherapy Equipment segment is expected to reach 0.265 USD Billion by 2035.

**Q: Which end-user segments are prominent in The Global Phototherapy?**
A: Prominent end-user segments in The Global Phototherapy include Clinics, Hospitals, and Dermatology Centers.

**Q: What was the valuation for Neonatal Jaundice Management in 2024?**
A: The valuation for Neonatal Jaundice Management was 0.2 USD Billion in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/phototherapy-market-1844*